6,678 trials
Pain
Primary: Maximal Pain/Discomfort — 4.7; 4.3; 5.0 units on a scale
Atherosclerosis · Endothelial Function
Primary: Number of Participants With Reduction of Thin-cap Fibroatheromas (TCFA) as Defined by VH-IVUS — 4; 6 participants
Acne Vulgaris
Primary: Percentage of Participants Who Remained Responders at Week 24 — 82 percentage of particpants — p=<.0001
Aging
Primary: Hydration Level — 53.19; 46.75 AU (arbitrary unit) — p=<0.05
Obesity
Primary: Gastric Emptying of Solids Half-Time (T 1/2) — 109; 88 minutes — p=0.057
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
HIV Infections
Primary: Number of Patients With Virological Failure (Two Consecutive Measures of HIV-RNA Higher Than 50 Copies/mL or a Single Measure Higher Than 1000 Copies/mL) Within 48 Weeks…
Dyslipidemias · Cardiovascular Diseases · Hypertriglyceridemia
Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change
Depressive Disorder, Major
Primary: Hamilton Depression Rating Scale (HDRS) — 7 participants — p=<.001
Fibromyalgia
Primary: Pain Threshold at Baseline — 2.7333; 2.583 kg/cm^2
Dupuytren's Disease
Primary: Clinical Success — 64.5; 45.0 percentage of particpants
Anesthesia, General
Primary: Time to Extubation — 13.0; 12.5 minutes
Infertility
Primary: MII Oocytes — 9.2; 10.3 cumulus oocyte complex
Anemia · Pregnancy Complications
Primary: Serum Ferritin Level — 136.1; 28.3 µg/dL
Smoking · Smoking Cessation · Adherence
Primary: Self-Reported 7-Day Point-Prevalence Abstinence — 197; 181; 202; 176 participants — p=.011